HARDMAN & CO RESEARCH Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital
Transparency directive : regulatory news
|
Hardman & Co Research
Analyst interview | Life Sciences Q&A on Shield Therapeutics (STX) | Positioned for profitability with Viatris deal and its additional capitaltive Shield Therapeutics (STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews. Martin summarises a number of announcements made by the company recently, explains Accrufer has performed in the US, a co-promotion deal with Viatris, changes made to the forecast and with the share price languishing what Martin expects to happen from here. Shield Therapeutics plc is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead medicine ACCRUFeR.
If you are interested in meeting the company, you can register your interest here
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
1541257 23-Jan-2023